Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

ABSTRACT:

Importance

Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines.

Objective

To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2 spike-specific humoral and cellular immune responses.

Design, setting, and participants

Twenty-five participants were enrolled from July 29, 2020, to August 7, 2020, and the follow-up for this day 71 interim analysis was completed on October 3, 2020; follow-up to assess durability will continue for 2 years. This study was conducted at a single clinical site in Boston, Massachusetts, as part of a randomized, double-blind, placebo-controlled phase 1 clinical trial of Ad26.COV2.S

SUBMITTER: Stephenson KE 

PROVIDER: S-EPMC7953339 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature